Physician profile
Robert M Yeh
NPI 1689856643
$15,631.99
in general payments reported to CMS, 2019-2025
30 companies · $3,595 in 2025
The $3,595 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $586 · 2021: $1,391 · 2022: $2,363 · 2023: $2,827 · 2024: $3,416 · 2025: $3,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,756 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,755.70 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,991.41 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Gilead Sciences, INC. | $3,352.40 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $746.55 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Redhill Biopharma INC. | $710.76 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Aimmune Therapeutics, INC. | $668.23 | 2024-2025 | Zenpep, Vowst |
| Intra-Sana Laboratories | $558.52 | 2021-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $524.66 | 2019-2025 | Relistor, Plenvu, Xifaxan |
| Phathom Pharmaceuticals, INC. | $507.03 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $484.17 | 2019-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $392.52 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $333.87 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $307.13 | 2019-2024 | Sutab, Suflave |
| Pfizer INC. | $258.51 | 2024-2025 | |
| Genzyme Corporation | $246.81 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $239.14 | 2020-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $212.21 | 2022-2023 | Linzess |
| Merck Sharp & Dohme LLC | $178.26 | 2019-2021 | |
| Novo Nordisk INC | $152.49 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $143.70 | 2019 | |
| Janssen Scientific Affairs, LLC | $118.74 | 2019 | |
| Celgene Corporation | $101.44 | 2021-2024 | Zeposia |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $100.53 | 2019 | |
| Boston Scientific Corporation | $84.81 | 2025 | General - Vascular Access |
| Covidien LP | $60.01 | 2019 | |
| Ferring Pharmaceuticals INC. | $37.88 | 2022-2024 | Rebyota |
| Fujifilm Healthcare Americas Corporation | $34.93 | 2020 | |
| Ucb, INC. | $32.32 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.66 | 2025 | Iqirvo |
| Ethicon US, LLC | $17.18 | 2020 | |
| Concordia Pharmaceuticals INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.